Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vidutolimod - Checkmate Pharmaceuticals

Next Previous
Drug Profile

Vidutolimod - Checkmate Pharmaceuticals

Alternative Names: ARB 1598; CMP-001; CYT 003 QbetaG10; CYT-003; CYT003 PolQb; CYT003 PolQbeta; CYT003-QbG10; Immunodrug™ CYT003-QbG10; IND#18627; QbG10; Virus-like particle-based cancer vaccine - Checkmate Pharmaceuticals; VLP-based cancer vaccine - Checkmate Pharmaceuticals

Latest Information Update: 26 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cytos Biotechnology
  • Developer Arbutus Biopharma; Bristol-Myers Squibb; Centre Hospitalier Universitaire Vaudois; Checkmate Pharmaceuticals; Cytos Biotechnology; Genocea Biosciences [CEASED]; Pfizer; Regeneron Pharmaceuticals; University of Pittsburgh
  • Class Allergy immunotherapies; Anti-inflammatories; Antiallergics; Antineoplastics; Cancer vaccines; Immunotherapies; Oligodeoxyribonucleotides; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants; Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Malignant melanoma
  • Phase II Head and neck cancer; Merkel cell carcinoma; Squamous cell cancer; Triple negative breast cancer
  • Phase I/II Lymphoma; Solid tumours
  • No development reported Colorectal cancer; Non-small cell lung cancer
  • Discontinued Allergic asthma; Atopic dermatitis; Hepatitis B; Perennial allergic rhinitis; Seasonal allergic rhinitis

Most Recent Events

  • 30 May 2025 Adverse event and efficacy data from a phase II trial in Malignant melanoma presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
  • 08 Apr 2025 Checkmate Pharmaceuticals completes a phase-I/II trial in Lymphoma (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (Intratumoural) (NCT03983668)
  • 17 Dec 2024 Regeneron Pharmaceuticals completes an Expanded Access programme for the compassionate use of vidutolimod (NCT06063746)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top